Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Pluripotent stem cell resources for mesodermal medicine (PLURIMES)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: United Kingdom,United Kingdom,Italy,France,Germany,United Kingdom,Netherlands,Switzerland,France,United Kingdom
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2014-02-01
End date: 2018-01-31
Duration (months): 48.0
Total project cost (EUR): 7690431.24
EU funding (EUR): 6000000.0
Participants: 12
Project status: CLOSED

Harnessing the capacity of pluripotent stem cells (PSCs) to produce functional cell types with precision and at scale will enable new treatment modalities for degenerative diseases. A major target for such therapies is mesodermal tissue, muscle, bone and cartilage. The goal of PluriMes is to create a bioengineering platform for directing PSCs into specific classes of mesodermal/mesenchymal progenitor. The project pulls together stem cell experts, genetic engineers, developmental biologists, cell therapy pioneers, bioengineers and specialist SMEs in a cross-disciplinary collaborative effort. Close-working between partners will be maximised through specialist workshops, laboratory exchange schemes, regular workpackage meetings, and joint Deliverables. The concept underlying PluriMes is that refined control of early fate decisions to produce correctly specified progenitors will be obtained through confronting developmental principles with engineering logic. We aim to define ground states and resolve issues of hierarchy, heterogeneity and stability in order to provide standardised PSC and mesodermal progenitor cell populations. A toolbox of fluorescent reporters will be developed for live cell tracking. Cutting edge bioengineering approaches will be implemented for dynamic topological administration of morphogens, matrices, small molecule modulators and siRNAs in 2D and 3D contexts. Through SME involvement, culture systems will be optimised for specification and subsequent stable expansion of mesodermal progenitors. The capacity of PSC-derived mesodermal cells for maturation into skeletal muscle, bone and cartilage will be tested in vitro and in vivo using lineage reporters. Potency will then be evaluated in pre-clinical disease models. Scale up protocols will be implemented in partnership with SMEs using the latest bioreactor technologies. Finally, GMP compliance and validated applicability to clinical grade stem cells will underpin future cell therapy propositions.

Keywords: stem cell,pluripotent,mesoderm,mesenchymal,bioengineering,cell therapy,genetic modification,muscular dystrophy,cell culture,regenerative medicine.
Supporting sustainable participation of industry, in particular high-technology, research-intensive SMEs in EU-funded research in the Health Sector (FIT FOR HEALTH 2.0)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: Austria,Germany,Germany,Germany,Netherlands,Greece,Belgium,Belgium,Romania,United Kingdom,Switzerland
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-11-01
End date: 2017-10-31
Duration (months): 48.0
Total project cost (EUR): 3031483.29
EU funding (EUR): 2478078.0
Participants: 12
Project status: CLOSED

Fit for Health 2.0 aims to promote and enhance a sustainable participation of European industry in the Health-related sector of Horizon 2020 (H2020). Focusing on research-intensive, high technology SMEs the project offers targeted support measures, covering the entire innovation cycle of research projects. Key assets are highly qualified advice and support including a mentoring and coaching approach, hands-on trainings, effective SME-academia matchmaking and guidance to use H2020 more strategically. SMEs and researchers will be supported during all phases of research projects, including first orientation, consortium building, proposal writing, project management and efficient valorisation of project results. Cooperation between SMEs and academia will be strongly encouraged by dedicated services and tools and using new media. A well established, highly visible database with a sophisticated matchmaking-tool together with the complementary BiotechGate database will support the formation of competitive project consortia. H2020-Partnering Days will provide excellent interaction platforms for SMEs and academia. Target group-specific on-site and virtual trainings for H2020 starters, applicants and participants of running FP7 Health-, IMI- and EDCTP projects will be a hallmark of the project. Partnering Days and trainings for exploitation will support SMEs and researchers in successfully bringing their project results to the market. A mentoring and coaching approach and strategy trainings will support SMEs and clusters for a sustainable participation in H2020. The consortium builds on the success of the running project Fit for Health. Highly experienced NCPs and Enterprise Europe Network-members together with renowned senior trainers on innovation, technology transfer, financing and IPR ensure perfect coverage of the entire innovation cycle. To maximize synergies, this efficiently managed network is strategically connected to other key support networks for SMEs.

Keywords: high tech research intensive smes,innovation,trainings,mentoring & coaching approach,sme-academia partnering
IMAging GEnetics for MENtal Disorders (IMAGEMEND)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,United Kingdom,Switzerland,Italy,United Kingdom,Germany,Norway,Netherlands,Iceland,Netherlands,Germany,Australia,United States
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-10-01
End date: 2017-09-30
Duration (months): 48.0
Total project cost (EUR): 8134274.27
EU funding (EUR): 6000000.0
Participants: 14
Project status: CLOSED

Mental disorders are leading causes of disability, absence from work and premature retirement in Europe. While magnetic resonance imaging (MRI) facilities are broadly available and a vast research literature exists, few neuroimaging applications have reached clinical practice in psychiatry. A major problem is that mental illnesses are currently diagnosed as discrete entities defined clinically. Instead, recent results show that mental disorders are best understood as quantitative alterations in neural systems relevant across traditional diagnostic boundaries that reflect individual, genetic and environmental risk factors. In the IMAGEMEND consortium, we aim to discover these systems to identify the patient characteristics most relevant for treatment, derive biomarkers and decision rules from this systems-level dimensional account, and systematically validate biomarker panels in patient, high-risk and epidemiological samples to produce automated imaging-based diagnostic and predictive tests tailored for wide distribution throughout Europe in standard clinical settings. Focusing on schizophrenia, bipolar disorder and attention deficit-hyperactivity disorder, we have assembled Europe’s largest dataset combining neuroimaging, genetic, environmental, cognitive and clinical information on approximately 13000 participants, and have recruited international replication datasets of more than 30000 people. This unique resource will be processed using a new generation of multivariate statistical analysis to optimize existing imaging technology for the benefit of patients. We will also develop new imaging technology to enable the direct imaging-based therapeutic modification of neural circuits through rapid real-time MRI. Our deliverables will promote personalized treatment through more accurate patient stratification, allow diagnoses at the pre-symptomatic stage for early intervention and prevention, and improve prediction of treatment response and disease progression.

Keywords: structural mri,resting state mri,real-time mri,imaging genetics,schizophrenia,bipolar disorder,attention deficit-hyperactivity disorder,multivariate analysis,biomarker panels
Adverse Immune Signatures and their Prevention in Corneal Transplantation (VISICORT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Ireland,Germany,United Kingdom,Denmark,Ireland,France,United Kingdom,Ireland,United Kingdom
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2014-04-01
End date: 2020-09-30
Duration (months): 78.0
Total project cost (EUR): 7910149.8
EU funding (EUR): 5989491.15
Participants: 13
Project status: CLOSED

Immune system response is the most complex barrier to long-term success of tissue transplants/implants from allogeneic and bio-artificial sources. While newly developed tissue transplant procedures are not yet performed frequently enough for robust analysis of adverse immune responses in humans, corneal transplantation (CT) is a well-established allogeneic tissue transplant with >100,000 full- and partial-thickness procedures performed annually. Adverse immune responses occur in up to 30% of CT recipients causing rejection and failure. The high levels of CT clinical activity and immune complications create an ideal opportunity to comprehensively profile immune responses associated with adverse tissue transplant outcomes and to develop new approaches for their prevention or early diagnosis. VISICORT is a multi-disciplinary project with expertise in basic immunology, bio-sampling, systems biology/immune profiling, bioinformatics, clinical tissue transplantation and cell therapy. It will complete the first systematic immune profiling of biological samples from animal and human CT recipients with diverse outcomes. Clinical data and bio-specimens from over 700 CT recipients at 5 leading transplant centres will be centrally collated and distributed to cutting-edge university- and SME-based laboratories for multi-platform profiling and integrated bioinformatics analyses. Profiling data will generate better understanding of adverse immune reactions to tissue transplants. This knowledge will be used to develop novel biomarker-based surveillance strategies and, coupled with SME-based expertise in cell product development, will also inform the design and initiation of an optimised clinical trial strategy of immunomodulatory stromal stem cell therapy in high-risk human CT recipients. VISICORT research will strongly impact multiple EU research/scientific communities, patient cohorts and SMEs and will have high commercialisation value for the biopharmaceutical and biotechnology industries.

Keywords: stem cells,transplant,implant,corneal transplant,large cohorts,new therapies,immune signatures,systems biology,bio-informatics,complications,surveillance,immunomodulatory stem cells
Development of Stem Cell Based Therapy for Thymic Regeneration (THYMISTEM)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: United Kingdom,Spain,Croatia,Ukraine,Türkiye,United States,Czechia
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-10-01
End date: 2017-09-30
Duration (months): 48.0
Total project cost (EUR): 7750649.62
EU funding (EUR): 5996455.47
Participants: 7
Project status: CLOSED

Reconstitution of immune system function in immunocompromised patients depends on the presence of a functional thymus, and specifically, on the diverse array of epithelial cells within the thymic stroma. The thymus is the first organ to degenerate in normal healthy individuals, and is also sensitive to cytotoxic interventions. Therefore lack of thymic function presents a serious problem for many patients. Transplantation of neonatal human thymus can lead to successful immune system reconstitution, but limited tissue supply prevents its widespread use. Thymic epithelial stem cells (TESC), which can generate all of the epithelial subpopulations of the adult thymus, present an alternative source of transplantable cells. However, protocols for growing or generating TESC in the laboratory have not yet been developed. This proposal aims to develop robust and scalable protocols for the long-term in vitro culture of functionally validated human TESC, including standardized quality controls, and to establish optimized means of delivering these cells to immunocompromised recipients such that thymus function is fully restored. It also aims to develop optimized procedures for cryopreservation of human thymic stromal cells. These objectives relate directly to the topic identified in call HEALTH.2013.1.4-1 Controlling differentiation and proliferation in human stem cells intended for therapeutic use. THYMISTEM brings together a strong, pan-European team comprising thymus and stem cell biologists, immunologists working in humanized mouse models, haematologists expert in immune reconstitution, tissue engineers, and experts in cryopreservation and cell banking, to deliver these goals. Overall, this work will build the preclinical foundations required for development of a novel stem-cell based therapy: transplantation of thymic epithelial stem cell-based organoids for regenerative recovery of thymic - and thus immune system - function in patients.

Keywords: stem cell,thymus,thymic epithelial stem cell,human,cell replacement,regeneration,transplantation,tissue engineering,immunosenescence,immunodeficiency,immune reconstitution,humanized mice.
An ethical, legal and practical perspective on the impact of a new regulatory framework for the scientific use of animals on research and innovation (ANIMPACT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: Portugal,Italy,Denmark,Germany,United Kingdom,Netherlands
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-10-01
End date: 2016-12-31
Duration (months): 39.0
Total project cost (EUR): 556820.81
EU funding (EUR): 498555.0
Participants: 6
Project status: CLOSED

Research with animals is considered necessary to obtain certain vital knowledge for advancing health research and innovation, but the harm such research may cause animals is ethically problematic. The European legislation regulating animal experimentation is based on the need to balance the two important interests at stake: advancing research and protecting animal welfare. The public sensitivity of the issue is evidenced by the exceptional participation in the legislative process leading to a revised European legislation. Directive 2010/63/EU (presently under transposition into Member State legislation) will bring about substantial changes compared to the previous directive dating from 1986. One of the main objectives of revising this legislation is to create a greater harmonization of the governance of the use of animals in scientific (including medical) research for the European research area. The transposition is being accompanied by European Commission initiatives to promote a common interpretation of the legislation. However, major determinants of how research in Europe will be affected remain largely uncharted, in that little is published about how legal, ethical and scientific decisions about research will be made and how regulation will influence these decisions. A multidisciplinary team of academic researchers from different EU Member States will use literature reviews, questionnaires, interviews, and focus groups to provide a deeper understanding of how the regulation interacts with research and innovation through the new common legal framework for animal experimentation in the EU. ANIMPACT will address the effectiveness of the new Directive and the current law in relation to other established norms in ethics, law, and scientific research, with focus on its interaction with ethics review and project licensing processes. The project will further consider the impact of the Directive on academic and commercial competitiveness as well as on animal welfare.

Keywords: directive 2010/63/eu,animals used for scientific purposes,animal welfare,effectiveness of law,research competitiveness,ethics review,harmonization,transparency
A dedicated trimodality (PET/MR/EEG) imaging tool for schizophrenia (TRIMAGE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Italy,Greece,Germany,Germany,Germany,Switzerland,France,France,Germany
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-12-01
End date: 2018-11-30
Duration (months): 60.0
Total project cost (EUR): 7975902.67
EU funding (EUR): 5994380.0
Participants: 12
Project status: CLOSED

Schizophrenia is a severe mental disorder that manifests early in life and imposes a high social and economic burden on European societies. An imaging tool that enables the diagnosis of schizophrenia during early development is extremely desirable and is requested by the clinical community in order to make the management of the disease more effective. TRIMAGE aims to optimise and validate an integrated diagnostic solution including simultaneous PET/MR/EEG imaging and specific biomarkers to provide the clinicians an effective tool for the diagnosis and choice of treatment of schizophrenia and other mental health disorders. Specific biomarkers using information from PET/MR, fMRI/EEG and PET/MR/EEG will be used to define the signature of the disease. The imaging hardware will be engineered with the intent of making the instrument a cost-effective and "beyond the state of the art" commercial product so as to provide a toolset for the diagnosis of patients in most clinical psychiatric centres. The instrument will comprise a 1.5 T cryogen-free, very compact superconducting magnet, a PET insert based on silicon photomultiplier with better performances (2 mm FWHM spatial resolution, 14% sensitivity at the center of the field of view) than any available clinical PET scanner and a fully integrated EEG. The adopted technology will reduce cost, simplify safety management, improve patient comfort and boost performance with respect to state of the art MRI and PET brain imagers. The tool design and construction requires scientific and technological developments in both the physical and medical fields: the work plan counts on the cooperation of highly qualified academic institutions and research centres with a major R&D contribution coming from four high technology European SMEs and Large Companies.

Keywords: brain pet,sipm,mri,fmri,1.5 t,eeg,trimodality imaging,schizophrenia,brain disorders,mental disorders,biomarkers
Mechanisms and Treatment of Migraine and its Chronification (EUROHEADPAIN)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,Belgium,Germany,United Kingdom,Finland,Australia,Italy,Germany,United States,Denmark,Hungary
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2014-02-01
End date: 2017-01-31
Duration (months): 36.0
Total project cost (EUR): 8197155.0
EU funding (EUR): 5996726.0
Participants: 14
Project status: CLOSED

Migraine is a common brain disorder, typically characterised by recurring, incapacitating attacks of 1-3 days of severe headache, autonomic dysfunction, and sometimes aura symptoms. The disease affects 15% of all European citizens including children, ranks among the WHO top 12 of most disabling and undertreated disorders, and is responsible for the highest socio-economic burden of any brain ailment in Europe. Migraine attacks typically strike bi-monthly, and in 25% of patients once a week or more. Many patients may progress to “chronic migraine” with near-daily headaches and high disability (chronification). There is desperate need of effective prophylactic treatments to prevent attacks and chronification. Current medications are only moderately effective and often poorly tolerated, mainly due to lack of understanding of how attacks are triggered and why their frequency may increase so dramatically. Overuse of painkillers and triptans, are recognised risk factors for chronification, as are comorbid depression, stress, and obesity. Central sensitisation of pain signalling pathways appears to be pivotal to the chronification proces. EUROHEADPAIN will use established and evolving human and translational animal models to: (a) identify pathways and biomarkers for the triggering and chronification of migraine attacks; (b) decipher the modulatory effects of (hypothalamic) brain circuitries on trigeminal processing, sensitisation, and chronification; (c) assess the effects and mode of action of migraine-provoking molecules; and (d) evaluate the efficacy and mode of action of neuromodulation (in collaboration with an SME) and second messenger-blocking drugs in the treatment of chronic migraine. We expect important spin-offs to the understanding of other chronic pain disorders. The pharmaceutical industry will be engaged once treatable targets have been identified to develop novel treatments to reduce the disability and socio-economic burden due to migraine.

Keywords: migraine,pain,triggering mechanisms,genetics,animal models,patients,treatment,prevention,pathways,biomarkers,brain circuitries,neuromodulation
Comparing policy framework, structure, effectiveness and cost-effectiveness of functional and integrated systems of mental health care (COFI)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: United Kingdom,Belgium,Germany,Italy,Poland
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2014-02-01
End date: 2018-05-31
Duration (months): 52.0
Total project cost (EUR): 6390191.4
EU funding (EUR): 4983127.0
Participants: 6
Project status: CLOSED

Mental disorders affect 38.2% of the EU population. For reducing the associated burden, countries across Europe engage in costly re-organizations of mental health care systems. Reforms focus on one controversial core question: Should systems be functional or integrated? In functional systems, separate staff in different services are in charge of in- and out-patient care (to enhance specialization). In integrated systems, the same staff are responsible across services (to strengthen co-ordination and avoid fragmentation). So far, there is no sound research evidence to inform the debate and far reaching policy decisions. Integrated and functional systems co-exist in some countries. This provides the unique chance to compare the effectiveness of the two systems independently of country specific contexts. We will conduct a large-scale comparison in countries with different traditions, levels of service provision and funding systems of mental health care (Belgium, Germany, Italy, Poland, United Kingdom). We will work as a multi-disciplinary team (psychiatrists, psychologists, nurses, sociologists, public health experts, health economists) and prospectively follow-up more than 5000 patients with major mental disorders over a 9 month period. Across countries, we will compare the effectiveness and cost-effectiveness for clinical and social outcomes (including quality of life), patients’ health and social needs, safety and quality of care of patients in the two systems. We will also establish how patients and clinicians experience the advantages and limitations of each system, and identify the policies and legislative frameworks determining practice in the two systems. We will produce guidelines for policies specifying in what context and for which patient groups (e.g. older age) functional or integrated systems are preferable, and disseminate these widely (to governments, scientific societies, professional bodies, users and carers’ organizations).

Keywords: health care systems,integrated care,functional care,mental health services